Genenta Science SpA ADR (GNTA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.70 (-8.17%), Market cap $0.01B, 52-week low–high $0.59 ~ $6.20.
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Financial statements, price targets, institutional (13F) holdings and related news for Genenta Science SpA ADR are updated in real time on BlackAll Trade.
Genenta Science SpA ADR trades at $0.70 (-8.17%). Real-time quotes and charts are available on BlackAll Trade.
Genenta Science SpA ADR has a market cap of about $0.01B.
Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Pha